ReviewBritish journal of pharmacology2015
Class A1 scavenger receptors in cardiovascular diseases.
Review in British journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Rhynchophylline alleviates early atherosclerosis by attenuating oxidized low-density lipoprotein-induced foam cell formation and endothelial dysfunction.Molecular and cellular biochemistry · 2026Article
- Investigation of the association between MSR1 serum levels and type 2 diabetes: a preliminary study.Irish journal of medical science · 2025Article
- Homocysteine affects macrophage polarization by altering m6A methylation of scavenger receptors CD209 and CD163L1.Epigenetics · 2024Article
- Class A1 scavenger receptor antibody improves murine colitis by influencing macrophage and gut microbiota.Scientific reports · 2024Article
- Macrophage scavenger receptor A1 promotes skeletal muscle regeneration after hindlimb ischemia.Journal of biomedical research · 2024Article
- Gsα Regulates Macrophage Foam Cell Formation During Atherosclerosis.Circulation research · 2024Article
- An update on ox-LDL-inducing vascular smooth muscle cell-derived foam cells in atherosclerosis.Frontiers in cell and developmental biology · 2024Review
- The role of foam cells in spinal cord injury: challenges and opportunities for intervention.Frontiers in immunology · 2024Review
- Liposomes-Based Drug Delivery Systems of Anti-Biofilm Agents to Combat Bacterial Biofilm Formation.Antibiotics (Basel, Switzerland) · 2023Review
- Regulation of activated microglia and macrophages by systemically administered DNA/RNA heteroduplex oligonucleotides.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Disruption of USP9X in macrophages promotes foam cell formation and atherosclerosis.The Journal of clinical investigation · 2022Article
- Inflammation: A New Look at an Old Problem.International journal of molecular sciences · 2022Review
- Macrophage scavenger receptors: Tumor support and tumor inhibition.Frontiers in oncology · 2022Review
- Foam Cells in Atherosclerosis: Novel Insights Into Its Origins, Consequences, and Molecular Mechanisms.Frontiers in cardiovascular medicine · 2022Review
- Macrophages in Atherosclerosis, First or Second Row Players?Biomedicines · 2021Review
- The Odd Faces of Oligomers: The Case of TRAF2-C, A Trimeric C-Terminal Domain of TNF Receptor-Associated Factor.International journal of molecular sciences · 2021Article
- Oleacein and Foam Cell Formation in Human Monocyte-Derived Macrophages: A Potential Strategy Against Early and Advanced Atherosclerotic Lesions.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Class A1 scavenger receptors mediated macrophages in impaired intestinal barrier of inflammatory bowel disease.Annals of translational medicine · 2020Article
- The scavenger receptor SCARA1 (CD204) recognizes dead cells through spectrin.The Journal of biological chemistry · 2019Article
- Immunobiology of Atherosclerosis: A Complex Net of Interactions.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Class A1 scavenger receptors (SR-A1) are membrane glycoproteins that can form homotrimers. This receptor was originally defined by its ability to mediate the accumulation of lipids in macrophages. Subsequent studies reveal that SR-A1 plays critical roles in innate immunity, cell apoptosis and proliferation. This review highlights recent advances in understanding the structure, receptor pathway and regulation of SR-A1. Although its role in atherosclerosis is disputable, recent discoveries suggest that SR-A1 function in anti-inflammatory responses by promoting an M2 macrophage phenotype in cardiovascular diseases. Therefore, SR-A1 may be a potential target for therapeutic intervention of cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.